{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039052","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.036769+00:00","generated_at":"2026-06-12T05:27:40.382715+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FibroGen Q2 revenue up 49% but net loss widens; multiple Phase 3 failures; new CEO appointed","bullets":["Q2 total revenue $44.3M (+49% YoY); net loss $87.7M ($0.90) vs $72.6M ($0.78) last year; includes $24.6M one-time charge.","Reported negative topline from three Phase 3 trials: MATTERHORN (roxadustat MDS), LELANTOS-1 (pamrevlumab DMD), ZEPHYRUS-1 (pamrevlumab IPF); ZEPHYRUS-2 discontinued.","China roxadustat net sales $76.4M (+44% YoY) driven by >40% volume growth; number one anemia brand in China.","Appointed Thane Wettig as Interim CEO; implemented cost reduction plan targeting $100-120M annualized GAAP expense savings.","Exclusive license for FOR46 (FG-3246) ADC targeting CD46 for mCRPC; $75M non-dilutive term loan from Morgan Stanley."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039052","json":"https://secwatch.observer/filing/0000950170-23-039052.json","markdown":"https://secwatch.observer/filing/0000950170-23-039052.md","text":"https://secwatch.observer/filing/0000950170-23-039052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017023039052/0000950170-23-039052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017023039052/fgen-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T05:27:40.382715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05bb8b0882f35d6db75aeec48ee2bfa5ece95b19","claim":"KYNTRA BIO, INC. reported second quarter 2023 results: revenue $44.3 million, net income $87.7 million, EPS $0.90 net loss per basic and diluted share.","evidence_excerpt":"the filing of two INDs: FG-3165 (anti-Gal9 antibody) in 1Q 2024 and FG-3175 (anti-CCR8 antibody) in 2H 2024. Financial: • Total revenue for the second quarter of 2023 was $44.3 million, as compared to $29.8 million for the second quarter of 2022, an increase of 49%. • Net loss for the second quarter of 2023 was $87.7 million, or $0.90 net loss per basic and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017023039052/0000950170-23-039052-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"$44.3 million"},{"label":"Net income","value":"$87.7 million"},{"label":"EPS","value":"$0.90 net loss per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}